Lineage Cell Therapeutics (LCTX) Misses Q2 EPS by 10c, Beats on Revenue

Lineage Cell Therapeutics (NYSE: LCTX) reported Q2 EPS of ($0.13), $0.10 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $2.77 million versus the consensus estimate of $1.48 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• First Farmers & Merchants Corp (FFMH) Declares $0.29 Quarterly Dividend; 2% Yield
• 8x8 reports data breach via third-party Salesforce integration